1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

The present Competitive Intelligence Report about Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

With the approval and launch of next generation Her2 antibodies Perjeta and Kadcyla, Roche has succeeded in boosting its Her2 franchise lead by Herceptin in 2013 to US$ 7.5 bln (+14% vs previous year).
The commercial attractiveness of trastuzumab has stimulated many companies to create and develop next generation anti-Her2 monoclonal antibodies (mabs) with improved properties compared with the humanized antibody trastuzumab. These biosuperior antibodies include antibody-drug conjugates, bi- and multispecific antibodies and engineered Her2 antibodies. The forthcoming patent expiry for Herceptin has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and launched in less regulated markets.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
Table of Contents
1. Trastuzumab Biosimilars and Biobetters/Biosuperiors

Marketed Her2 Antibodies

-           Herceptin Sales and Pipeline

-           Perjeta Sales and Pipeline

-           Kadcyla Sales and Pipeline

Trastuzumab Biobetters/Biosuperiors

-           Engineered Her2 Antibodies

-           Bi- and Multispecific Her2 Antibodies

-           Her2 Antibody-Drug Conjugates

-           Her2 Imaging Antibodies

Trastuzumab Biosimilars
2.  Corporate Her2 Antibody Biosimilar and Biobetter Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking ...

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.